Patent 8957040 was granted and assigned to Ionis Pharmaceuticals on February, 2015 by the United States Patent and Trademark Office.
Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).